NCT00030225View on ClinicalTrials.gov

Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions
Fulminant Hepatic Failure
Interventions
BIOLOGICAL

ELAD

OTHER

Standard of care (Control)

Trial Locations (7)

15213

University of Pittsburgh, Pittsburgh

22908

University of Virginia, Charlottesville

30322

Emory School of Medicine, Atlanta

33136

University of Miami, Miami

60637

University of Chicago, Chicago

92103

UCSD, San Diego

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Vital Therapies, Inc.

INDUSTRY

NCT00030225 - Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure | Biotech Hunter | Biotech Hunter